Immuno-oncology
From the Journals
First reported case of induced resistance to tisagenlecleucel
The CAR gene was unintentionally introduced into a single leukemic B cell during T-cell manufacturing.
Latest News
Researchers share Nobel Prize for cancer immunotherapy discoveries
Dr. James P. Allison and Dr. Tasuku Honjo share the Nobel Prize for their work on preventing brakes on T cells, which led to the development of...
From the Journals
Endogenous retroviruses may unlock new immunotherapy targets
Future epigenetic drugs could activate human endogenous retroviruses (HERVs) in cancer cells to enable immunotherapy, investigators suggest.
...Conference Coverage
PACIFIC trial: Durvalumab improves both OS and PFS in stage III NSCLC
TORONTO – Updated PACIFIC trial results show that durvalumab provides first major OS, PFS advance for stage III NSCLC in decades.
Conference Coverage
CAR T-cell studies dominate ongoing cellular therapy trials
Out of 753 cellular therapy trials listed at ClinicalTrials.gov as of March 30, 2018, 404 were CAR T therapy studies.
From the Journals
Dramatic response from pembrolizumab in patient with Lynch syndrome
A woman with two distinct primary tumors caused by Lynch syndrome achieved complete regression of both after pembrolizumab therapy.
From the Journals
PD-1/PD-L1 treatment linked to hyperprogressive disease in lung cancer patients
Nearly 14% of NSCLC patients treated with PD/1/PD-L1 inhibitors had hyperprogressive disease, compared with about 5% of patients treated with...
From the Journals
Fatal toxicities from checkpoint inhibitors vary by agent
Cardiac and neurologic toxicities accounted for nearly half of all toxicities associated with cancer therapy with immune checkpoint inhibitors.
From the Journals
Kymriah cost effectiveness depends on long-term outcomes
The value proposition for the pricey CAR T-cell therapy depends on whether the real-world outcomes are as good as the ones seen in clinical trials...
From the Journals
Skin signs may be good omens during cancer therapy
Vitiligo, rash, nail changes, and other cutaneous toxicities are associated with good clinical outcomes with three major classes of cancer...
From the Journals
HIV-associated Kaposi sarcoma responds to checkpoint inhibitors
Checkpoint inhibitor therapy is effective for patients with HIV-associated Kaposi sarcoma (KS), a recent study has found.
Partial or...